PBLS Parabilis Medicines, Inc.
$36.88▲ +1.54%
Healthcare
Other
After hours
$36.88▲ +0.00%
Sep 11, 7:30 PM ET
Volume 364.8K
Avg Volume (10D) 469.1K
Key Metrics & Fundamentals
Market Cap
$4.56B
P/E Ratio
–
Div Yield
–%
52W Range
24.51 - 41.49
% vs 50 MA
5.64%
% vs 200 MA
–%
RSI-14
46.4
MACD Histogram
-0.5200
Beta (1Y vs SPY)
-0.52
Free Cash Flow
-$4.24M
Gross Rev
$148,000
Gross Profit
$148,000
EBITDA
-$51.66M
COGS
–
Operating Exp
$51.03M
Operating Income
-$50.89M
EBIT
-$50.89M
Pretax Income
-$52.46M
Net Income
-$52.46M
EPS (Diluted)
-0.54
Price & Volume History
Loading chart…
Recent News
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire · Sep 1, 2026 11:00 AM
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
GlobeNewswire · Aug 25, 2026 11:00 AM
Young startups miss out on biotech venture funding rebound, MassBio says
BioPharma Dive · Aug 25, 2026 12:01 AM
Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell
MT Newswires · Aug 13, 2026 11:46 AM
Parabilis Medicines: Q2 Earnings Snapshot
Associated Press · Aug 13, 2026 11:07 AM
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire · Aug 13, 2026 11:00 AM
Parabilis Medicines (PBLS) Stock Valuation After Recent 10% Single Day Decline
Simply Wall St. · Jun 15, 2026 9:14 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See PBLS's money flow as a full page
Social Sentiment
No Reddit posts found for PBLS.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.